 Recent advancements in RNA-based therapeutics have opened up a new era of drug discovery and development. Small biotechnology companies and academic researchers alike have been able to quickly develop novel RNA-based drugs that target previously untreatable pathways. Additionally, these drugs are cost-effective, easy to manufacture, and can be tailored to individual patients. This has led to rapid growth in the field of RNA-based therapeutics, which is now being used in clinical trials and has even received regulatory approval. Despite the promise of RNA-based therapeutics, there remain several challenges and limitations that must be addressed before they can become widely adopted. To address these issues, we propose the establishment of a hospital-based RNA therapeutics platform, which would allow for quicker translation of RNA-based therapeutics into clinical practice. This article was authored by Tulsi Ramdhamase, Roman Sokovarshin, Christian Boda, and others.